Beta Bionics, Inc. SEC Filings

Stephen Feider, Chief Financial Officer of Beta Bionics, Inc. (BBNX), reported transactions dated 08/22/2025. He exercised an employee stock option with a $5.10 exercise price to acquire 4,413 shares and immediately sold those 4,413 shares pursuant to a Rule 10b5-1 plan adopted May 15, 2025, at a weighted average sale price of $17.014 per share (range $17.00–$17.12). After these transactions his beneficial ownership declined from 49,916 shares to 45,503 shares. The option vests in 48 equal monthly installments beginning 09/14/2023 and expires 09/13/2033.

Form 144 notice for Beta Bionics, Inc. (BBNX) reports a proposed sale of 4,413 shares of common stock through Merrill Lynch on 08/22/2025 with an aggregate market value of $75,082.65. The filing lists total shares outstanding of 43,470,125. The shares to be sold were acquired on 08/22/2025 as stock options from Beta Bionics and the stated payment method is cash. The filing also discloses two prior sales by Stephen Feider on 06/02/2025 (1,497 shares, $26,783.06) and 08/19/2025 (5,587 shares, $95,171.78).

Mark Hopman, Chief Commercial Officer of Beta Bionics, Inc. (BBNX), reported coordinated transactions on 08/19/2025 under a Rule 10b5-1 plan adopted May 13, 2025. He exercised an employee stock option with a $5.10 exercise price to acquire 16,158 shares. The same day he sold 16,158 shares pursuant to the 10b5-1 plan at a weighted average sale price of $16.6095, with reported price range of $16.26 to $17.1719. The filing shows beneficial ownership counts of 50,290 shares following the acquisition line and 34,132 shares following the reported sale; the derivative table reports 16,158 option shares underlying and 67,084 total shares beneficially owned following the derivative transaction line. The form is signed by an attorney-in-fact on 08/20/2025.

Stephen Feider, Chief Financial Officer of Beta Bionics, Inc. (BBNX), reported insider transactions on 08/19/2025. He acquired 5,587 shares via an employee stock option with an exercise price of $5.10 and immediately sold 5,587 shares pursuant to a Rule 10b5-1 plan at a weighted average price of $17.034505 (price range $17.00–$17.095). After these transactions his direct beneficial ownership decreased from 51,090 shares to 45,503 shares. The option shares vest in 48 equal monthly installments measured from September 14, 2023, and the related option lists an exercisable/expiration reference dated 09/13/2033.

Form 144 notice from Beta Bionics, Inc. (BBNX) records a proposed sale of 5,587 common shares through Merrill Lynch on the NASDAQ with an aggregate market value of $95,171.78, listed for sale on 08/19/2025. The shares were acquired by stock option from Beta Bionics with payment in cash on the same date. The filing also discloses a prior sale by Stephen Feider of 1,497 shares on 06/02/2025 for $26,783.06. By signing, the seller represents no undisclosed material adverse information exists and acknowledges potential criminal penalties for false statements.

Form 144 notice for Beta Bionics (BBNX) reports a proposed sale of 16,158 common shares through Merrill Lynch with an aggregate market value of $268,376.10. The filing lists 43,470,125 shares outstanding and an approximate sale date of 08/19/2025 on NASDAQ. The securities were acquired the same day (08/19/2025) via a stock option from Beta Bionics and payment is listed as cash. The filing also discloses a prior sale by Mark Hopman of 868 shares on 06/02/2025 for $15,529.00. The signer certifies they have no undisclosed material information and provides the standard Rule 10b5-1 and legal attestations.

This Schedule 13G/A discloses significant beneficial ownership positions in Beta Bionics common stock by Zone Healthcare, multiple Farallon-managed funds, their management company and numerous Farallon individual reporting persons. Zone Healthcare Holdings, LLC and Farallon Capital Management, L.L.C. are each reported with shared voting and dispositive power over 3,277,220 shares (7.6% of the class). Several Farallon funds disclose smaller direct holdings (examples include 166,877 and 380,597 shares). A set of Farallon individual reporting persons are each shown with an aggregate beneficial amount of 4,203,920 shares (9.7% of the class), and the filing states these individuals may be deemed beneficial owners based on their roles while disclaiming beneficial ownership.

The filing is submitted pursuant to the passive investor provision of the rules and includes a certification that the securities were not acquired to change or influence control. The Reporting Persons indicate they neither affirm nor disclaim the existence of a group among them and include standard power-of-attorney signatures for the reporting entities and individuals.

Beta Bionics reports that Sands Capital Life Sciences Pulse Fund II, Sands Capital Alternatives, LLC and Frank M. Sands jointly beneficially own 3,570,113 shares of common stock, equal to 8.2% of the class based on 43,470,125 shares outstanding as reported July 25, 2025. The filing shows 0 shares of sole voting or dispositive power and 3,570,113 shares of shared voting and dispositive power. The reporting parties file jointly and certify the holdings were not acquired to change or influence control of the issuer.

Morgan Stanley and its subsidiary Morgan Stanley Capital Services LLC have filed a Schedule 13G disclosing beneficial ownership of approximately 2.93 million Beta Bionics (BBNX) common shares, representing 6.8 % of the outstanding class as of 30 June 2025. All voting (2.93 m) and dispositive (2.93 m) rights are reported as shared; the firms hold no sole authority.

The filing was made under Rule 13d-1(b), signalling a passive investment. Morgan Stanley is classified as a parent holding company (HC), while the subsidiary is a broker-dealer (BD). The certification states the position was acquired in the ordinary course of business and not to influence control. A near-7 % institutional stake from a globally recognised financial institution may enhance BBNX’s liquidity, analyst coverage and investor credibility.